Charles Cliff Duncan net worth and biography

Charles Duncan Biography and Net Worth

Director of Vanda Pharmaceuticals

Charles C. Duncan, Ph.D. has served as President of Sulci Advisors, LLC, a life sciences-focused business advisory firm he founded in September 2025. Prior to that, Dr. Duncan served as Managing Director and Senior Biotechnology Analyst at Cantor Fitzgerald & Co. from July 2018 until his retirement in June 2025, where he covered more than 70 companies with a focus on neurology, psychiatry, and platform-enabled therapeutics. From December 2012 to June 2018, he served as Managing Director and Senior Biotechnology Analyst at Piper Jaffray & Co., and from September 2002 to December 2012 as Managing Director and Senior Biotechnology Analyst at JMP Securities, LLC, where he was a founding healthcare partner. Earlier in his career, Dr. Duncan held biotechnology equity research positions at several firms and co-founded InfusionVision MEDical, Inc., a venture capital-backed medical device company. Dr. Duncan received his Ph.D. in Pharmaceutical Sciences, with a concentration in Neuropharmacology, from the University of Colorado-Boulder and his B.S. in Zoology from the University of Wisconsin-Madison.

What is Charles Cliff Duncan's net worth?: The estimated net worth of Charles Cliff Duncan is at least $369.40 thousand as of November 4th, 2026. Dr. Duncan owns 102,898 shares of Vanda Pharmaceuticals stock worth more than $369,404 as of November 6th. This net worth estimate does not reflect any other assets that Dr. Duncan may own. Learn More about Charles Cliff Duncan's net worth.
How do I contact Charles Cliff Duncan?: The corporate mailing address for Dr. Duncan and other Vanda Pharmaceuticals executives is 2200 Pennsylvania Ave NW, Suite 300e, Washington, DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Charles Cliff Duncan's contact information.
Has Charles Cliff Duncan been buying or selling shares of Vanda Pharmaceuticals?: During the past quarter, Charles Cliff Duncan has bought $38,068.94 in shares of Vanda Pharmaceuticals stock. Most recently, on Thursday, November 5th, Charles Cliff Duncan bought 5,803 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $22,051.40. Following the completion of the transaction, the director now directly owns 108,701 shares of the company's stock, valued at $413,063.80. Learn More on Charles Cliff Duncan's trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Gunther Birznieks (SVP), Phaedra Chrousos (Director), Charles Duncan (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), Joakim Wijkstrom (CMO), and Timothy Williams (SVP). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, Vanda Pharmaceuticals insiders bought shares 3 times. They purchased a total of 10,000 shares worth more than $38,068.94. In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 314,342 shares worth more than $2,583,984.84. The most recent insider tranaction occured on November, 5th when Director Charles Cliff Duncan bought 5,803 shares worth more than $22,051.40. Insiders at Vanda Pharmaceuticals own 10.7% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 11/5/2026.

Charles Cliff Duncan Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/5/2026	Buy	5,803	$3.80	$22,051.40	108,701
11/4/2026	Buy	3,447	$3.82	$13,167.54	102,898
11/3/2026	Buy	750	$3.80	$2,850.00	99,451

Charles Cliff Duncan Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $3.59

$3.57

$3.88

50 Day Range

MA: $4.66

$3.59

$5.53

2 Week Range

Now: $3.59

$3.57

$9.94

Volume

1,239,112 shs

Average Volume

1,211,088 shs

Market Capitalization

$217.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74